Health care for osteoporosis in inflammatory bowel disease: Unmet needs in care of male patients?

Journal of Crohn's and Colitis

Volumn 7, Issue 11, 2013, Pages 901-907

  Walldorf, Jens ^a   Krummenerl, Annette ^b   Engler, Kristin ^a   Busch, Juliane ^a   Dollinger, Matthias M ^c   Seufferlein, Thomas ^c   Albert, Jörg G ^d  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b Hospital Martha Maria Halle Dölau   (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Colitis ulcerosa; Crohn's disease; Inflammatory bowel disease; Osteoporosis

Indexed keywords

CORTICOSTEROID; MERCAPTOPURINE;

ADULT; ARTICLE; BONE DENSITY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; FRACTURE; HEALTH CARE QUALITY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; TOBACCO DEPENDENCE; ULCERATIVE COLITIS;

COLITIS ULCEROSA; CROHN'S DISEASE; INFLAMMATORY BOWEL DISEASE; OSTEOPOROSIS;

ABSORPTIOMETRY, PHOTON; ADULT; AGE FACTORS; BONE DENSITY; BONE DISEASES, METABOLIC; COHORT STUDIES; COLITIS, ULCERATIVE; COMORBIDITY; CROHN DISEASE; DELIVERY OF HEALTH CARE; FEMALE; GERMANY; HUMANS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; NEEDS ASSESSMENT; OSTEOPOROSIS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEX FACTORS;

EID: 84884812604     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.12.008     Document Type: Article

References (36)

1. Von Tirpitz C., Steder-Neukamm U., Glas K., Sander S., Ring C., Klaus J., et al. Osteoporosis in inflammatory bowel disease - results of a survey among members of the German Crohn's and Ulcerative Colitis Association. Z Gastroenterol 2003, 41:1145-1150.
2. Bjarnason I., Macpherson A., Mackintosh C., Buxton-Thomas M., Forgacs I., Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut 1997, 40:228-233.
3. Boubaker J., Feki M., Hsairi M., Fekih M., Kaabachi N., Filali A., et al. Osteoporosis and inflammatory bowel disease: prevalence and risk factors in Tunisian patients. Gastroenterol Clin Biol 2003, 27:901-907.
4. Bernstein C.N., Leslie W.D. Review article: osteoporosis and inflammatory bowel disease. Aliment Pharmacol Ther 2004, 19:941-952.
5. Schulte C., Dignass A.U., Mann K., Goebell H. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflamm Bowel Dis 1998, 4:268-275.
6. Loftus E.V., Crowson C.S., Sandborn W.J., Tremaine W.J., O'Fallon W.M., Melton L.J. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology 2002, 123(2):468-475.
7. Vestergaard P., Krogh K., Rejnmark L., Laurberg S., Mosekilde L. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut 2000, 46(2):176-181.
8. Vestergaard P. Prevalence and pathogenesis of osteoporosis in patients with inflammatory bowel disease. Minerva Med 2004, 95(6):469-480.
9. Miheller P., Lorinczy K., Lakatos P.L. Clinical relevance of changes in bone metabolism in inflammatory bowel disease. World J Gastroenterol 2010, 16(44):5536-5542. [28].
10. Bernstein C.N., Blanchard J.F., Leslie W., Wajda A., Yu B.N. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000, 133(10):795-799.
11. Klaus J., Armbrecht G., Steinkamp M., Brückel J., Rieber A., Adler G., et al. High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut 2002, 51(5):654-658.
12. Hoffmann J.C., Preiss J.C., Autschbach F., Buhr H.J., Häuser W., Herrlinger K., et al. Clinical practice guideline on diagnosis and treatment of Crohn's disease. Z Gastroenterol 2008, 46(9):1094-1146.
13. Van Assche G., Dignass A., Reinisch W., van der Woude C.J., Sturm A., De Vos M., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis 2010, 4:63-101.
14. Bartram S.A., Peaston R.T., Rawlings D.J., Francis R.M., Thompson N.P. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment Pharmacol Ther 2003, 18:1121-1127.
15. Kane S., Reddy D. Guidelines do help change behaviour in the management of osteoporosis by gastroenterologists. Am J Gastroenterol 2006, 101:1841-1844.
16. Wagnon J.H., Leiman D.A., Ayers G.D., Schwartz D.A. Survey of gastroenterologists' awareness and implementation of AGA guidelines on osteoporosis in inflammatory bowel disease patients: are the guidelines being used and what are the barriers to their use?. Inflamm Bowel Dis 2009, 15:1082-1089.
17. Van Staa T.P., Cooper C., Brusse L.S., Leufkens H., Javaid M.K., Arden N.K. Inflammatory bowel disease and the risk of fracture. Gastroenterology 2003, 125:1591-1597.
18. Mittermayer V., Müller V.E., Albert J., Allolio B., Blind E., Böhning W., et al. Prophylaxe, Diagnostik und Therapie der Glukokortikoid-induzierten Osteoporose. Osteologie 2003, 12:70-88.
19. Dignass A., Preiss J.C., Aust D.E., Autschbach F., Ballauff A., Barretton G., et al. Updated German guideline on diagnosis and treatment of ulcerative colitis. Z Gastroenterol 2011, 49:1276-1341.
20. Biancone L., Michetti P., Travis S., Escher J.C., Moser G., Forbes A., et al. European evidence-based consensus on the management of ulcerative colitis: special situations. J Crohns Colitis 2008, 2:63-92.
21. Kirchgatterer A., Wenzl H.H., Aschl G., Hinterreiter M., Stadler B., Hinterleitner T.A., et al. Examination, prevention and treatment of osteoporosis in patients with inflammatory bowel disease: recommendations and reality. Acta Med Austriaca 2002, 29:120-123.
22. Walsh L.J., Wong C.A., Pringle M., Tattersfield A.E. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996, 313:344-346.
23. Etzel J.P., Larson M.F., Anawalt B.D., Collins J., Dominitz J.A. Assessment and management of low bone density in inflammatory bowel disease and performance of professional society guidelines. Inflamm Bowel Dis 2011, 17:2122-2129.
24. Kanis J.A., Johnell O., Oden A., Johansson H., McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008, 19:385-397.
25. Robinson R.J., Al-Azzawi F., Iqbal S.J., Kryswcki T., Almond L., Abrams K., et al. Osteoporosis and determinants of bone density in patients with Crohn's disease. Dig Dis Sci 1998, 43:2500-2506.
26. Bartram S.A., Peaston R.T., Rawlings D.J., Walshaw D., Francis R.M., Thompson N.P. Multifactorial analysis of risk factors for reduced bone mineral density in patients with Crohn's disease. World J Gastroenterol 2006, 12:5680-5686.
27. Van Schaik F.D., Verhagen M.A., Siersema P.D., Oldenburg B. High prevalence of low bone mineral density in patients with inflammatory bowel disease in the setting of a peripheral Dutch hospital. J Crohns Colitis 2008, 2:208-213.
28. Atreja A., Aggarwal A., Licata A.A., Lashner B.A. Low body mass index can identify majority of osteoporotic inflammatory bowel disease patients missed by current guidelines. Sci World J 2006, 807438.
29. Schoon E.J., Van Nunen A.B., Wouters R.S., Stockbrügger R.W., Russel M.G. Osteopenia and osteoporosis in Crohn's disease: prevalence in a Dutch population-based cohort. Scand J Gastroenterol Suppl 2000, (232):43-47.
30. Pigot F., Roux C., Chaussade S., Hardelin D., Pelleter O., Du Puy Montbrun T., et al. Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci 1992, 37:1396-1403.
31. Stockbrugger R.W., Schoon E.J., Bollani S., Mills P.R., Israeli E., Landgraf L., et al. Discordance between the degree of osteopenia and the prevalence of spontaneous vertebral fractures in Crohn's disease. Aliment Pharmacol Ther 2002, 16:1519-1527.
32. Klaus J., Haenle M.M., Schroter C., Adler G., von Boyen G., Reinshagen M., et al. A single dose of intravenous zoledronate prevents glucocorticoid therapy-associated bone loss in acute flare of Crohn's disease, a randomized controlled trial. Am J Gastroenterol 2011, 106:786-793.
33. Klaus J., Reinshagen M., Herdt K., Adler G., von Boyen G.B., von Tirpitz C. Intravenous ibandronate or sodium-fluoride - a 3.5years study on bone density and fractures in Crohn's disease patients with osteoporosis. J Gastrointestin Liver Dis 2011, 20:141-148.
34. Klaus J., Reinshagen M., Herdt K., Schröter C., Adler G., von Boyen G.B., et al. Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D. World J Gastroenterol 2011, 17:334-342.
35. Siffledeen J.S., Fedorak R.N., Siminoski K., Jen H., Vaudan E., Abraham N., et al. Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease. Clin Gastroenterol Hepatol 2005, 3:122-132.
36. Van Hogezand R.A., Hamdy N.A. Skeletal morbidity in inflammatory bowel disease. Scand J Gastroenterol Suppl 2006, 243:59-64.